Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics

The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America.
Neutralisation titres for Omicron were boosted following a third dose with Vaxzevria compared to titres after a second dose.(1)